Company intelligence / Profile preview

immunAware

Ownership: Private
Development stage: Commercial

Overview

immunAware provides advanced tools for the study of T cell responses by enabling precise monitoring and characterization of antigen-specific T cells. Their technologies have been instrumental in COVID‑19 vaccine research and oncology studies. They offer custom solutions for pharmaceutical and biotech companies to assess potential T cell targets using high-quality peptide-MHC reagents. No clinical results as they are not a therapeutic company.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Protein (recombinant MHC molecules)Peptides (peptide-MHC complexes)Biologic (custom pMHC reagents)
Industry: Drug Discovery Services

Partnerships

University of Copenhagen/Laboratory of Experimental Immunologybioinformatics collaborators on NetMHC series predictors

Beyond the preview

Go deeper on immunAware.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on immunAware.

Explore the full profile